Farmakovijilansın Önemi: Sahte ve Standart Altı İlaçlar

Year 2024, Volume: 33 Issue: 2, 86 - 90, 30.06.2024

Yusuf Karataş

https://doi.org/10.17827/aktd.1462835

Abstract

The scope of pharmacovigilance has expanded dramatically in recent years. In addition to the need of monitoring adverse drug reactions, it also involves counterfeit/substandard drugs, drug efficacy issues, misuse, and drug abuse. It is documented that among the drugs used for the treatment of patients with a high demand are counterfeited. All healthcare professionals (medical doctor/physicians, pharmacists, dentists, nurses, midwives, and paramedics) must raise awareness about counterfeit/substandard pharmaceuticals, as well as promote preventive measures in this area. The purpose of this review was provide information about counterfeit and substandard drugs that may lead to an increase morbidity and mortality in humans. This article emphasizes the importance of a pharmacovigilance system to combat hazardious effects of counterfeit/substandard drugs on public health.

Farmakovijilansın kapsamı son yıllarda önemli ölçüde genişlemiştir. Advers ilaç reaksiyonlarının önemi ve izlenmesine ilaveten sahte/standart altı ilaçları, ilaçların etkinliğinin eksikliğini, yanlış kullanımı, ilacın kötüye kullanımını da içermektedir. Hastaların tedavisi kullanılan ilaçlardan yüksek oranda talep edilen pahalı ilaçların sahtelerinin yapıldığı belirtilmektedir. Tüm sağlık çalışanları (tıp doktorları, eczacılar, diş hekimleri, hemşireler, ebeler, ve paramedikler), sahte/standart altı ilaçları vd. farkındalıkların artırılması ve bu konuda önleyici çalışmaların artırılması gerekmektedir. Bu derlemenin amacı, insanlarda morbidite ve mortalitede artışa yol açabilecek sahte ve standart altı ilaçlar hakkında bilgi vermektir. Bu derleme, sahte/standart altı ilaçların halk sağlığı üzerindeki zararlı etkileriyle mücadele etmek için farmakovijilans sisteminin önemini vurgulamaktadır

Keywords

Farmakovijilans, Sahte ilaç, Standart altı ilaç, Sağlık çalışanları

References

• 1. World Health Organization. https://www.who.int/data/gho/data/major-themes/health-and-well-being 28.03.2024
• 2. World Health Organization. The safety of medicines in public health programmes: pharmacovigilance an essential tool. World Health Organization, 2006. https://apps.who.int/iris/handle/10665/43384.
• 3. Khan Z, Karataş Y, Rahman H. Adverse drug reactions reporting in Turkey and barriers: an urgent need for pharmacovigilance education. Ther Adv Drug Saf. 2020;11:1-3.
• 4. World Health Organization Programme for International Drug Monitoring. Members of the WHO Programme for International Drug Monitoring. 2023. https://www.who-umc.org/global- pharmacovigilance/who-programme-for-international-drug-monitoring/who-programme-members/.
• 5. World Health Organization. Ensuring medicines work safely for everyone. 2021. https://www.who.int/news/item/02-11-2020-ensuring-medicines-work-safely-for-everyone.
• 6. Wertheimer AI, Chaney NM, Santella T Counterfeit pharmaceuticals: current status and future projections. J Am Pharm Assoc. 2003; 43(6):710-8. doi:10.1331/154434503322642642.
• 7. Coleman JJ, Pontefract SK. Adverse drug reactions. Clin Med (Lond). 2016;16(5):481-485.
• 8. Pathak R., Gaur V., Sankrityayan H., Gogtay J. Tackling Counterfeit Drugs: The Challenges and Possibilities. Pharmaceutical Medicine https://doi.org/10.1007/s4029002300468-w
• 9. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/substandard-and-falsified-medical-products 28.03.2024
• 10. https://gun.av.tr/insights/articles/comment-closing-the-gap-counterfeit-drugs-in-turkey#top 28.03.2024
• 11. Rang HP, Ritter JM, Flower RJ. Rang And Dale’s Pharmacology. 8th ed. London, Elsevier, 2016, pp 1-5
• 12. Sipahi H., Peltekoglu K., Şencan N. Adverse effects of counterfeit drugs on public health İstanbul Ecz. Fak. Derg. / J. Fac. Pharm. Istanbul 2014; 44(1):89-99.
• 13. https://www.ema.europa.eu/en/medicines/human/EPAR/iclusig 28.03.2024
• 14. World Health Organization https://www.who.int/news/item/01-02-2019-medical-product-alert-n-2-2019 28.03.2024
• 15. https://www.cumhuriyet.com.tr/turkiye/sahte-ilac-2021010 28.03.2024
• 16. https://www.uspharmacist.com/article/counterfeit-meds 28.03.2024
• 17. https://www.psi-inc.org/therapeutic-categories 28.03.2024
• 18. Substandard medicines: a greater problem than counterfeit medicines? | BMJ Paediatrics Open https://bmjpaedsopen.bmj.com/content/1/1/bmjpo-2017-000007
• 19. Johnston A., Holt DW. Substandard drugs: a potential crisis for public health, Br J Clin Pharmacol. 2014 Aug; 78(2): 218–243. doi: 10.1111/bcp.12298
• 20. World Health Organization https://www.who.int/news-room/fact-sheets/detail/substandard-and-falsified-medical-products 30.03.2024
• 21. Almuzaini T., Choonara I., Sammons H. Substandard and counterfeit medicines: a systematic review of the literature. BMJ Open. 2013;3:e002923.doi:10.1136/bmjopen-2013-002923
• 22.https://titck.gov.tr/storage/Archive/2022/announcement/SahteKaakveyaYasalTedarikZinciriDnakmlalarHakkndaKlavuz_65f3163e-2025-48cf-8b32-1c1e6e2146dd.pdf 01.04.2024